View Item 

Show simple item record

Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis
dc.contributor.authorWaljee, A. K.
dc.contributor.authorLiu, B.
dc.contributor.authorSauder, K.
dc.contributor.authorZhu, J.
dc.contributor.authorGovani, S. M.
dc.contributor.authorStidham, R. W.
dc.contributor.authorHiggins, P. D. R.
dc.date.accessioned2018-03-07T18:25:46Z
dc.date.available2019-05-13T14:45:25Zen
dc.date.issued2018-03
dc.identifier.citationWaljee, A. K.; Liu, B.; Sauder, K.; Zhu, J.; Govani, S. M.; Stidham, R. W.; Higgins, P. D. R. (2018). "Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis." Alimentary Pharmacology & Therapeutics 47(6): 763-772.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/142532
dc.publisherWiley Periodicals, Inc.
dc.titlePredicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142532/1/apt14510_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142532/2/apt14510.pdf
dc.identifier.doi10.1111/apt.14510
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceLoftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504 ‐ 1517.
dc.identifier.citedreferenceFeagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699 ‐ 710.
dc.identifier.citedreferenceStallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Aliment Pharmacol Ther. 2016; 44: 1199 ‐ 1212.
dc.identifier.citedreferenceAmiot A, Serrero M, Peyrin‐Biroulet L, et al. One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017; 46: 310 ‐ 321.
dc.identifier.citedreferenceDulai PS, Singh S, Jiang X, et al. The real‐world effectiveness and safety of vedolizumab for moderate‐severe Crohn’s disease: results from the US VICTORY consortium. The American journal of gastroenterology. 2016; 111: 1147 ‐ 1155.
dc.identifier.citedreferenceENTYVIO (VEDOLIZUMAB) FOR INJ 300MG SDV. metromedicalorder.com. https://www.metromedicalorder.com/entyvio-vedolizumab-for-inj-300mg-sdv.html. Accessed March 20, 2017.
dc.identifier.citedreferenceCohen BL, Sachar DB. Update on anti‐tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017; 357: j2505. https://doi.org/10.1136/bmj.j2505
dc.identifier.citedreferenceCSDR: Clinical Study Data Request. https://clinicalstudydatarequest.com/.
dc.identifier.citedreferenceBreiman L. Random forests. Mach Learn. 2001; 45: 5 ‐ 32.
dc.identifier.citedreferenceLiaw A, Wiener M. Classification and regression by random forest. R News. 2002; 2: 18 ‐ 22.
dc.identifier.citedreferenceRomero J, Lopez P, Vazquez Noguera JL, Cappo C, Pinto‐Roa PD, Villalba C. Integrated, reliable and cloud‐based personal health record: a scoping review. HIIJ. 2016; 5: 01 ‐ 20.
dc.identifier.citedreferenceStidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014; 39: 660 ‐ 671.
dc.identifier.citedreferenceStidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014; 39: 1349 ‐ 1362.
dc.identifier.citedreferenceOlivera P, Danese S, Peyrin‐Biroulet L. JAK inhibition in inflammatory bowel disease. Exp Rev Clin Immunol. 2017; 13: 693 ‐ 703.
dc.identifier.citedreferenceFurfaro F, Gilardi D, Allocca M, et al. IL‐23 Blockade for Crohn s disease: next generation of anti‐cytokine therapy. Exp Rev Clin Immunol. 2017; 13: 457 ‐ 467.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt14510_am.pdf
Size:
316.3KB
Format:
PDF
View/Open
Name:
apt14510.pdf
Size:
1.023MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.